Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SEER data: Abiraterone acetate may up mortality risk in prostate cancer patients with CVD

Key clinical point: Abiraterone acetate treatment may increase mortality risk in prostate cancer patients with CVD.

Major finding: Mortality rates after AA initiation were 21.4%-25.6% in patients with CVD vs. 15.8% in those without CVD.

Study details: A review of SEER-Medicare linked data for 2,845 patients.

Disclosures: This study was funded by a Pennsylvania CURE Program award and the National Cancer Institute. Dr. Lu-Yao has no direct conflicts to declare except that her spouse, who has no involvement with this study, is an officer of Sun Pharmaceutical Industries Inc.

Citation:

Lu-Yao G et al. AACR 2019, Abstract preview.